Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 17Carcinoma, Hepatocellular 4Stomach Neoplasms 1Prostate Adenocarcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Lobular 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1Biochemically Recurrent Prostate Carcinoma 1

Interventions

pembrolizumab 3lenvatinib 3gallium 68 PSMA-11 2apatinib 2Protons 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Epirubicin 2Cisplatin 2Carboplatin 2Axitinib 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2tislelizumab 1regorafenib 1enfortumab vedotin 1cabozantinib 1avelumab 1anlotinib 1amivantamab 1abemaciclib 1Tretinoin 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sunitinib 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Radiation 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Adenoid Cystic × 68Ga-DKFZ-PSMA-11 × Clear all
NCT06521775 2025-09-12

An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma

Mayo Clinic

Phase 2 Completed
6 enrolled

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡